The effects of rutin flavonoid supplement on glycemic status, lipid profile, atherogenic index of plasma, brain‐derived neurotrophic factor (BDNF), some serum inflammatory, and oxidative stress factors in patients with type 2 diabetes mellitus: A double‐blind, placebo‐controlled trial

This study aimed to investigate the effects of rutin flavonoid in type 2 diabetes mellitus (T2DM) patients. In this trial (double‐blind, placebo‐controlled), 50 T2DM patients (supplement, n = 25 and placebo, n = 25) were randomized and supplemented with 500 mg rutin or placebo per day for 3‐months....

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2023-01, Vol.37 (1), p.271-284
Main Authors: Bazyar, Hadi, Moradi, Leila, Zaman, Ferdows, Zare Javid, Ahmad
Format: Article
Language:English
Subjects:
Antioxidants - metabolism
Antioxidants - pharmacology
Antioxidants - therapeutic use
BDNF
Beta cells
Blood Glucose
Brain
Brain-derived neurotrophic factor
Brain-Derived Neurotrophic Factor - metabolism
Cholesterol
Cholesterol, LDL
Density
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Double-Blind Method
Double-blind studies
Flavonoids
Flavonoids - pharmacology
Glycated Hemoglobin
Hemoglobin
High density lipoprotein
Homeostasis
Humans
Inflammation
Insulin
Insulin resistance
Insulin Resistance - physiology
Interleukin 6
Interleukin-6 - metabolism
Lipids
Lipoproteins (very low density)
Low density lipoprotein
Mathematical models
metabolic parameters
Metabolism
Oxidative Stress
Parameters
Placebos
Rutin
Rutin - pharmacology
Rutin - therapeutic use
Triglycerides
type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to investigate the effects of rutin flavonoid in type 2 diabetes mellitus (T2DM) patients. In this trial (double‐blind, placebo‐controlled), 50 T2DM patients (supplement, n = 25 and placebo, n = 25) were randomized and supplemented with 500 mg rutin or placebo per day for 3‐months. At the beginning and at the end of the study, metabolic parameters including fasting blood glucose (FBG), insulin, glycosylated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMO‐IR), quantitative insulin sensitivity check index (QUICKI), homeostasis model assessment of β‐cell function (HOMA‐β), triglyceride (TG), total cholesterol (CHOL), high‐density and low‐density lipoprotein cholesterol (HDL‐c and LDL‐c), and atherogenic index of plasma (AIP), inflammatory and oxidative stress markers such as interleukin 6 (IL‐6), total antioxidant capacity (TAC), and malondialdehyde (MDA) and brain‐derived neurotrophic factor (BDNF) were assessed. The results showed a significant decrease in FBG, insulin, HbA1c, HOMO‐IR, LDL‐c, TG, VLDL, CHOL, LDL‐c.HDL‐c ratio, AIP, IL‐6, and MDA and a significant increase in HDL‐c, QUICKI index, BDNF, and TAC compared with the initial value (p for all
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.7611